Drugs for Lipid Metabolism Disease

Drugs for Lipid Metabolism Disease Market Outlook

The global Lipid Metabolism Disease Drugs Market is projected to reach approximately USD 20 billion by 2035, growing at a CAGR of around 5% from 2025 to 2035. This growth is primarily driven by an increasing prevalence of lipid metabolism disorders, lifestyle changes leading to obesity, and the rising awareness of cardiovascular diseases. Additionally, the global push towards preventive healthcare and advancements in pharmaceutical research are contributing to the market's expansion. The growing aging population is more prone to lipid metabolism diseases, which further bolsters the demand for effective drug therapies in this area. Furthermore, the surge in innovative drug development, particularly in the areas of PCSK9 inhibitors and novel formulations, is expected to propel the market significantly during the forecast period.

Growth Factor of the Market

The Lipid Metabolism Disease Drugs Market is experiencing significant growth due to several interlinked factors. The rising prevalence of lifestyle-related diseases such as obesity and type 2 diabetes has led to an increasing number of individuals diagnosed with lipid metabolism disorders. As healthcare systems globally emphasize preventive measures, there is a concurrent rise in awareness regarding the need for lipid management and the associated pharmacotherapy options available. Additionally, technological advancements in drug formulation and delivery systems, such as long-acting injectables and combination therapies, have improved treatment adherence and patient outcomes, contributing further to market growth. The lucrative nature of the market has also attracted investments in research and development, resulting in the introduction of new drugs and therapies aimed at managing lipid disorders more effectively. Lastly, favorable reimbursement policies in various regions are also facilitating easier access to lipid-lowering medications.

Key Highlights of the Market

• The market is projected to grow at a CAGR of 5% from 2025 to 2035.
• Statins remain the dominant drug class due to their widespread use and effectiveness.
• Regionally, North America holds the largest market share, driven by high healthcare spending.
• Online pharmacies are becoming increasingly popular, enhancing drug accessibility.
• Innovative therapies, particularly PCSK9 inhibitors, are expected to gain significant traction.

By Drug Class

Statins:

Statins are the most extensively prescribed class of drugs for managing lipid metabolism disorders, particularly hypercholesterolemia. They work by inhibiting the HMG-CoA reductase enzyme, which plays a crucial role in cholesterol biosynthesis in the liver. This action significantly lowers LDL cholesterol levels, thereby reducing the risk of cardiovascular events. Statins have a robust clinical history, supported by numerous studies highlighting their efficacy and safety. Their popularity is further augmented by extensive clinical guidelines recommending their use for primary and secondary prevention of cardiovascular diseases. However, the market is witnessing the emergence of alternatives, leading to growing competition within this drug class. Despite this, statins are expected to maintain a substantial market share due to their established track record and broad acceptance among healthcare professionals.

Fibrates:

Fibrates are another important class of drugs used primarily to treat high triglyceride levels and to a lesser extent, to increase HDL cholesterol levels. They function by activating peroxisome proliferator-activated receptors (PPARs), which play a role in lipid metabolism. Fibrates are particularly effective in patients who have mixed dyslipidemia, where multiple lipid abnormalities coexist. Although they are less commonly used than statins, they are essential for specific patient populations, particularly those who are statin-intolerant. The development of combination therapies that incorporate fibrates and statins has also gained traction, enhancing their therapeutic profile. As awareness regarding lipid disorders continues to expand, the role of fibrates in lipid management is expected to remain relevant, contributing to their sustained market presence.

PCSK9 Inhibitors:

PCSK9 inhibitors represent a groundbreaking advancement in lipid-lowering therapies, particularly for patients with familial hypercholesterolemia and those at high cardiovascular risk. These monoclonal antibodies work by inhibiting the PCSK9 protein, which leads to increased LDL receptor recycling in the liver and consequently lowers circulating LDL cholesterol levels. This novel mechanism of action sets them apart from traditional therapies. The introduction of these agents has been transformative, offering significant cholesterol reduction potential, even in patients who have exhausted other treatment options. Despite their high cost compared to statins, the clinical benefits and growing body of evidence supporting their use are driving increased adoption. The future of PCSK9 inhibitors in the Lipid Metabolism Disease Drugs Market appears promising, especially as more generics enter the market, which could enhance affordability.

Bile Acid Sequestrants:

Bile acid sequestrants are a unique class of drugs that lower LDL cholesterol by binding bile acids in the intestine, leading to increased conversion of cholesterol into bile acids. Although they are not as commonly prescribed as statins or fibrates, they play a critical role in lipid management, especially in patients with statin intolerance or those requiring additional LDL reduction. The efficacy of bile acid sequestrants is well-documented, but their usage can be limited by gastrointestinal side effects and potential drug interactions. Nevertheless, the increasing focus on personalized medicine and combination therapies is likely to sustain the relevance of bile acid sequestrants in specific patient populations with complex lipid profiles.

Omega-3 Fatty Acids:

Omega-3 fatty acids have gained popularity as dietary interventions for managing dyslipidemia, primarily due to their ability to lower triglyceride levels. These compounds can be obtained from various sources, including fish oil, and have been shown to have additional cardiovascular benefits. Omega-3s are particularly useful in patients with high triglyceride levels who may not be adequately managed by statins alone. The market for omega-3 fatty acids is growing as clinical guidelines increasingly recommend their use in conjunction with other lipid-lowering agents. Furthermore, the expanding knowledge around the anti-inflammatory properties of omega-3 fatty acids is enhancing their appeal as a therapeutic option, thus ensuring their ongoing presence in the lipid management landscape.

By Route of Administration

Oral:

Oral administration is the most common route for lipid metabolism disease drugs, primarily due to its ease of use and convenience for patients. Most lipid-lowering medications, including statins, fibrates, and bile acid sequestrants, are available in oral formulations, allowing for straightforward integration into daily routines. The oral route is also associated with better patient adherence compared to injectable alternatives, largely because patients prefer pills over injections. Pharmaceutical advancements have enhanced the bioavailability and efficacy of oral lipid-lowering therapies, leading to improved treatment outcomes. The popularity of this administration route is likely to persist, driven by ongoing innovation in drug formulations and the development of fixed-dose combinations that simplify dosing regimens for patients.

Parenteral:

Parenteral administration of lipid metabolism disease drugs primarily includes injectable therapies, such as PCSK9 inhibitors. This route is particularly valuable for patients who require rapid effects or those who are not adequately controlled on oral medications. Parenteral formulations can offer significant advantages, including higher bioavailability and the potential for less frequent dosing, which may enhance patient adherence. However, the higher cost and the need for healthcare provider administration can deter some individuals from choosing this route. As the clinical landscape evolves, the role of parenteral administration in lipid management is expected to expand, particularly as more patients seek tailored therapy options that meet their specific health needs.

By Distribution Channel

Hospital Pharmacies:

Hospital pharmacies play a crucial role in the distribution of lipid metabolism disease drugs, particularly for patients requiring inpatient treatment or those recently diagnosed. These pharmacies are well-equipped to provide comprehensive medication management, ensuring that patients receive the most appropriate therapies tailored to their medical conditions. In addition to dispensing medications, hospital pharmacies often collaborate with healthcare teams to optimize treatment regimens and monitor patient outcomes closely. As the demand for specialized care in managing lipid disorders grows, hospital pharmacies are likely to expand their offerings, including access to the latest lipid-lowering agents and therapeutic innovations.

Retail Pharmacies:

Retail pharmacies serve as a primary source for patients seeking lipid metabolism disease drugs, providing widespread access to various medications. They cater to the everyday needs of patients, offering convenience in obtaining prescriptions and over-the-counter options for managing lipid disorders. Retail pharmacies often have a more extensive reach than hospital pharmacies, allowing them to effectively serve urban and rural populations alike. Additionally, pharmacists play a pivotal role in educating patients about their medications, potential side effects, and lifestyle modifications necessary for effective lipid management. As healthcare trends shift towards community-based care, retail pharmacies are expected to remain a vital component of the distribution landscape for lipid metabolism drugs.

Online Pharmacies:

Online pharmacies are increasingly becoming an essential distribution channel for lipid metabolism disease drugs, especially in the wake of the growing digital health trend. They offer convenience and anonymity for patients, allowing them to order medications from the comfort of their homes. The rise of telemedicine has also facilitated the growth of online pharmacies, as patients can easily obtain prescriptions electronically and have their medications delivered directly. This method of distribution is particularly appealing to individuals who may feel stigmatized by their condition or those who prefer to avoid long wait times at traditional pharmacies. The ongoing expansion of online pharmacies is likely to enhance patient access to lipid-lowering therapies, contributing to improved treatment adherence and outcomes.

By Indication

Hypercholesterolemia:

Hypercholesterolemia is one of the primary indications for lipid metabolism disease drugs, characterized by elevated levels of cholesterol in the bloodstream. This condition poses significant risks, including cardiovascular diseases such as heart attacks and strokes. Statins are the first-line treatment for hypercholesterolemia, effectively reducing LDL cholesterol levels and improving overall lipid profiles. Given the increasing incidence of hypercholesterolemia due to lifestyle factors, there is a strong demand for effective treatment options. The market for hypercholesterolemia is witnessing growth as healthcare providers emphasize the importance of early detection and management, resulting in a more proactive approach to lipid regulation.

Hypertriglyceridemia:

Hypertriglyceridemia is another critical indication for lipid metabolism disease drugs, defined by elevated triglyceride levels in the blood. This condition can lead to serious health complications, including pancreatitis and cardiovascular events. Fibrates and omega-3 fatty acids are commonly used to address hypertriglyceridemia, often employed in conjunction with statins for comprehensive lipid management. As awareness of triglyceride-related health risks increases, so does the demand for effective therapies targeting this condition. The growing body of evidence regarding the role of triglycerides in cardiovascular disease is expected to drive market growth for drugs aimed at managing hypertriglyceridemia.

Dyslipidemia:

Dyslipidemia, characterized by abnormal lipid levels in the blood, encompasses a spectrum of conditions, including both hypercholesterolemia and hypertriglyceridemia. The complexity of dyslipidemia requires a multifaceted approach to treatment, often involving a combination of different lipid-lowering agents. Statins, fibrates, and PCSK9 inhibitors are integral to managing dyslipidemia effectively. The increasing recognition of the importance of lipid management in reducing cardiovascular risk is anticipated to further fuel the growth of dyslipidemia treatment options. As healthcare providers continue to prioritize individualized therapy plans, the market for dyslipidemia drugs will likely expand, catering to the diverse needs of patients.

By Region

North America is currently the largest market for lipid metabolism disease drugs, accounting for over 40% of the global share. The region's dominance is primarily attributed to high healthcare expenditure, advanced healthcare infrastructure, and a growing prevalence of lifestyle-associated diseases leading to lipid metabolism disorders. The United States, in particular, showcases a high number of patients being diagnosed and treated for conditions like hypercholesterolemia and dyslipidemia. Furthermore, increasing public awareness regarding the importance of lipid management and the availability of innovative therapies contribute to the market's growth in North America, with a projected CAGR of 5.5% over the next decade. In comparison, Europe holds a substantial market share, driven by similar factors, including rising healthcare investments and a focus on preventative care strategies.

In Asia Pacific, the lipid metabolism disease drugs market is expected to witness significant growth, with a projected CAGR of approximately 6% from 2025 to 2035. Rising urbanization, changing dietary patterns, and increased sedentary lifestyles are contributing to the higher incidence of lipid disorders in this region. Countries such as China and India are experiencing a surge in cardiovascular diseases, leading to an increased demand for effective lipid-lowering therapies. Latin America and the Middle East & Africa are also emerging markets where there is a growing recognition of lipid management's importance, although they currently hold a smaller share of the market compared to North America and Europe. As healthcare systems in these regions continue to develop and access to treatments improves, the overall market for lipid metabolism drugs is expected to expand.

Opportunities

The Lipid Metabolism Disease Drugs Market is rife with opportunities, particularly as healthcare continues to evolve towards more tailored and personalized approaches. One key opportunity lies in the development of combination therapies that leverage the strengths of multiple drug classes to achieve optimal lipid control. As healthcare providers increasingly recognize the value of personalized medicine, there is a growing demand for treatments that can be specifically tailored to individual patient profiles, including genetic factors and comorbidities. This trend opens avenues for pharmaceutical companies to innovate and develop multi-faceted therapies, thereby enhancing treatment adherence and patient outcomes. Furthermore, ongoing clinical trials and research into novel lipid-lowering agents, including small molecules and gene therapies, present significant prospects for market expansion, as these innovations may provide new solutions for patients who are resistant to current therapies.

Another opportunity arises from the rising trend of digital health solutions, which are transforming how patients manage their lipid levels. Mobile applications, telemedicine services, and wearable technology are increasingly utilized to monitor lipid profiles and enhance patient engagement in their healthcare. Pharmaceutical companies that integrate digital health strategies with their products can improve patient adherence and outcomes while capturing valuable real-time data on treatment effectiveness. Collaborations between pharmaceutical firms and technology companies can lead to the development of comprehensive platforms that offer personalized recommendations and support for patients managing lipid metabolism disorders. As the market continues to adapt to these emerging trends, companies that seize these opportunities are likely to be well-positioned for success in a competitive landscape.

Threats

The Lipid Metabolism Disease Drugs Market faces several threats that could impede its growth in the coming years. One of the primary concerns is the increasing prevalence of generic drugs and biosimilars that are entering the market. As patents for several blockbuster lipid-lowering drugs expire, numerous generics are becoming available at significantly reduced prices. This pricing pressure can lead to decreased revenues for branded drugs and can shift patient preferences toward cheaper alternatives, potentially undermining the market for innovative therapies. Additionally, regulatory challenges and stringent approval processes for new drug applications can delay the introduction of novel therapies, hindering market growth. Moreover, the potential for adverse effects associated with lipid-lowering medications may lead to increased scrutiny from regulatory bodies, creating hurdles for companies in bringing their products to market.

Another factor that poses a significant threat is the rising awareness of non-pharmacological interventions for managing lipid disorders, such as lifestyle modifications, dietary changes, and exercise. As individuals become more health-conscious, there may be a shift toward preventive measures that reduce the reliance on pharmaceuticals. This trend could result in a decreased demand for lipid-lowering drugs, as patients actively seek to manage their conditions through natural means. Additionally, the growing preference for holistic approaches to healthcare could complicate the commercialization of conventional lipid-lowering therapies, thereby challenging pharmaceutical companies to adapt their strategies to align with changing consumer preferences and expectations.

Competitor Outlook

• Pfizer Inc.
• Novartis AG
• Amgen Inc.
• Bristol-Myers Squibb Company
• Sanofi S.A.
• GlaxoSmithKline plc
• AstraZeneca PLC
• AbbVie Inc.
• Regeneron Pharmaceuticals, Inc.
• Merck & Co., Inc.
• Alnylam Pharmaceuticals, Inc.
• Mylan N.V.
• Hoffmann-La Roche Ltd.
• Eli Lilly and Company
• Takeda Pharmaceutical Company Limited

The competitive landscape of the Lipid Metabolism Disease Drugs Market is characterized by numerous established pharmaceutical companies and emerging biotech firms striving to gain market share through innovation and strategic partnerships. Major players like Pfizer, Novartis, and Amgen are investing heavily in research and development to create next-generation lipid-lowering therapies that offer improved efficacy and safety profiles. These companies often engage in extensive clinical trials to validate their products and secure regulatory approvals, which is a critical step in establishing their presence in this competitive market. Moreover, the trend toward collaboration—both within the pharmaceutical industry and with technology firms—is gaining traction, as companies seek to enhance their product offerings and tap into digital health solutions that can improve patient management and adherence.

Among the key competitors, Pfizer Inc. stands out with its extensive portfolio of lipid-lowering medications, including the widely recognized statin, atorvastatin. The company's ongoing commitment to innovation has led to the development of new formulations and combination therapies, positioning it as a leader in the market. Novartis is also a major player, known for its focus on innovative treatments for lipid disorders, including its developments in PCSK9 inhibitors. Additionally, Amgen has made significant strides in the market with its PCSK9 inhibitor, evolocumab, which has garnered considerable attention for its efficacy in lowering LDL cholesterol levels in high-risk patients. These companies leverage their extensive resources to drive research initiatives, enabling them to remain at the forefront of lipid metabolism drug innovation.

Emerging companies such as Regeneron Pharmaceuticals and Alnylam Pharmaceuticals are also making their mark, particularly in the realm of novel therapies and genetic approaches to lipid management. Regeneron's focus on developing monoclonal antibodies for lipid disorders has positioned it uniquely in the market, while Alnylam's work on RNA interference technology highlights the potential for groundbreaking treatments that could redefine how lipid metabolism disorders are approached. The continuous evolution of the competitive landscape, driven by innovation, strategic alliances, and a focus on meeting patient needs, ensures a vibrant and dynamic environment for lipid metabolism disease drugs in the coming years.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Amgen Inc.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Mylan N.V.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 AbbVie Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Novartis AG
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Pfizer Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Sanofi S.A.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 AstraZeneca PLC
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Merck & Co., Inc.
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 GlaxoSmithKline plc
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Eli Lilly and Company
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Hoffmann-La Roche Ltd.
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Bristol-Myers Squibb Company
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Alnylam Pharmaceuticals, Inc.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Regeneron Pharmaceuticals, Inc.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Takeda Pharmaceutical Company Limited
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Drugs for Lipid Metabolism Disease Market, By Drug Class
    • 6.1.1 Statins
    • 6.1.2 Fibrates
    • 6.1.3 PCSK9 Inhibitors
    • 6.1.4 Bile Acid Sequestrants
    • 6.1.5 Omega-3 Fatty Acids
  • 6.2 Drugs for Lipid Metabolism Disease Market, By Indication
    • 6.2.1 Hypercholesterolemia
    • 6.2.2 Hypertriglyceridemia
    • 6.2.3 Dyslipidemia
  • 6.3 Drugs for Lipid Metabolism Disease Market, By Distribution Channel
    • 6.3.1 Hospital Pharmacies
    • 6.3.2 Retail Pharmacies
    • 6.3.3 Online Pharmacies
  • 6.4 Drugs for Lipid Metabolism Disease Market, By Route of Administration
    • 6.4.1 Oral
    • 6.4.2 Parenteral

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Drugs for Lipid Metabolism Disease Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Drugs for Lipid Metabolism Disease market is categorized based on

By Drug Class

• Statins
• Fibrates
• PCSK9 Inhibitors
• Bile Acid Sequestrants
• Omega-3 Fatty Acids

By Route of Administration

• Oral
• Parenteral

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Indication

• Hypercholesterolemia
• Hypertriglyceridemia
• Dyslipidemia

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Pfizer Inc.
• Novartis AG
• Amgen Inc.
• Bristol-Myers Squibb Company
• Sanofi S.A.
• GlaxoSmithKline plc
• AstraZeneca PLC
• AbbVie Inc.
• Regeneron Pharmaceuticals, Inc.
• Merck & Co., Inc.
• Alnylam Pharmaceuticals, Inc.
• Mylan N.V.
• Hoffmann-La Roche Ltd.
• Eli Lilly and Company
• Takeda Pharmaceutical Company Limited